Global Cell Therapy Market—Companies to Action, 2018

Global Cell Therapy Market—Companies to Action, 2018

A Collaborative Business Model With Focus on Stem Cells, Chimeric Antigen Receptor T (CAR-T) Cells and Combination Therapies Will Propel Market Growth

RELEASE DATE
11-Mar-2019
REGION
North America
Research Code: PA16-01-00-00-00
SKU: HC03141-NA-MR_22920
AvailableYesPDF Download
$3,000.00
In stock
SKU
HC03141-NA-MR_22920
$3,000.00
DownloadLink
ENQUIRE NOW

Description

The global pharmaceutical industry is continuously evolving. with the rising need for novel therapies in the ever-changing disease landscape. As a result of rising prevalence of chronic infectious diseases as well as continuously growing number of cancer cases, market needs are shifting from traditional, small molecules to novel, large-molecule therapies, with cell therapies dominating the space. The study on the "Global Cell Therapy Market, 2018, Companies to Action” presents an overview of the global cell therapy landscape, with an emphasis on the key game-changing companies disrupting this market. The study highlights the emerging companies across regions that support the development and manufacturing of novel cell therapies.

With the changing market landscape, big pharma and biopharma participants, are looking toward the adoption of a collaborative business approach by either entering into co-development and/or co-commercialization agreements or acquiring smaller, niche participants so as to achieve a competitive advantage with respect to a specific therapy area or technology. The study also delves into some of the leading strategies adopted by market participants in order to succeed in this highly dynamic market. In addition to the above-mentioned strategic analysis, information such as risk sharing and fast to market business models of some of the emerging business models across the cell therapy market is also provided.


Research Highlights

This study identifies some of the strategies adopted by these game-changing companies with respect to key market-growth opportunities such as the use of combination therapies, manufacturing advancement and automation, adoption of newer gene-editing technologies such as CRISPR/Cas9, and so on. The study also highlights some collaborations and partnerships between these disruptive participants and throws some light on their upcoming drug pipeline; thereby, highlighting their contribution to this market. Additionally, it gives an insight into the leading strategic imperatives shaping the global industry and its long-term implication on market growth.

Key Issues Addressed

  • What are the key market opportunities in the global cell therapy market?
  • What is the impact of external industry environment on market growth?
  • Which are some of the unique participants that are introducing cutting-edge therapies in this segment?
  • What are the strategic imperatives to be adopted by these participants to bring about this market transformation?
  • What is the growth potential of this rapidly expanding cell therapy market?
  • What are some key factors for success in the global cell therapy market?

Table of Contents

Key Findings—Analysis of Companies to Action

Key Findings—Analysis of Companies to Action (continued)

Scope and Segmentation

Key Questions Addressed in this Study

Companies to Action Value Creators

Opportunities and Threats

Market Definitions

Market Segmentation

Cell Therapy Value Chain

Vendor Ecosystem

Impact of Key Market Influencers

Top 3 Trends and Vendor Strategies

Key Market Participants Aligned with Top 3 Trends

Cell Therapy—Vendor Landscape

Juno Therapeutics—Overview

Juno Therapeutics—Technology Platforms

Juno Therapeutics—Major Partnerships and Agreements

bluebird bio—Business Overview

bluebird bio—Technology Platform

bluebird bio—Major Partnerships and Agreements

Kite Pharma—Overview

Kite Pharma—Key Technology/ Product/Services

Kite Pharma—Case Example and Recent Developments

Adaptimmune—Overview

Adaptimmune—Technology Platforms

Adaptimmune—Case Example and Recent Developments

Oxford BioMedica—Overview

Oxford BioMedica—Technology Platform

Oxford BioMedica—Case Example and Recent Developments

JCR Pharmaceuticals—Overview

JCR Pharmaceuticals—Technology Platforms

JCR Pharmaceuticals—Case Example and Recent Developments

Sangamo Therapeutics—Company Overview

Sangamo Therapeutics—Value Proposition

DiscGenics—Company Overview

DiscGenics—Value Proposition

TiGenix—Company Overview

TiGenix—Value Proposition

Bone Therapeutics—Company Overview

Bone Therapeutics—Value Proposition

Cell Medica—Company Overview

Cell Medica—Value Proposition

Mesoblast—Company Overview

Mesoblast—Value Proposition

Cynata Therapeutics—Company Overview

Cynata Therapeutics—Value Proposition

Medipost—Company Overview

Medipost—Value Proposition

Anterogen—Company Overview

Anterogen—Value Proposition

Pharmicell—Company Overview

Pharmicell—Value Proposition

Short Profiles of Digital Pathology Companies

Short Profiles of Digital Pathology Companies (continued)

Short Profiles of Digital Pathology Companies (continued)

Short Profiles of Digital Pathology Companies (continued)

Transformation in the Industry Ecosystem

Five Major Growth Opportunities

Strategic Imperatives for Growth

Conclusion—Key Takeaways

Legal Disclaimer

Abbreviation List

List of Exhibits

List of Exhibits (continued)

The Frost & Sullivan Story

Value Proposition—Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

Related Research
The global pharmaceutical industry is continuously evolving. with the rising need for novel therapies in the ever-changing disease landscape. As a result of rising prevalence of chronic infectious diseases as well as continuously growing number of cancer cases, market needs are shifting from traditional, small molecules to novel, large-molecule therapies, with cell therapies dominating the space. The study on the "Global Cell Therapy Market, 2018, Companies to Action” presents an overview of the global cell therapy landscape, with an emphasis on the key game-changing companies disrupting this market. The study highlights the emerging companies across regions that support the development and manufacturing of novel cell therapies. With the changing market landscape, big pharma and biopharma participants, are looking toward the adoption of a collaborative business approach by either entering into co-development and/or co-commercialization agreements or acquiring smaller, niche participants so as to achieve a competitive advantage with respect to a specific therapy area or technology. The study also delves into some of the leading strategies adopted by market participants in order to succeed in this highly dynamic market. In addition to the above-mentioned strategic analysis, information such as risk sharing and fast to market business models of some of the emerging business models across the cell therapy market is also provided.--BEGIN PROMO--

Research Highlights

This study identifies some of the strategies adopted by these game-changing companies with respect to key market-growth opportunities such as the use of combination therapies, manufacturing advancement and automation, adoption of newer gene-editing technologies such as CRISPR/Cas9, and so on. The study also highlights some collaborations and partnerships between these disruptive participants and throws some light on their upcoming drug pipeline; thereby, highlighting their contribution to this market. Additionally, it gives an insight into the leading strategic imperatives shaping the global industry and its long-term implication on market growth.

Key Issues Addressed

  • What are the key market opportunities in the global cell therapy market?
  • What is the impact of external industry environment on market growth?
  • Which are some of the unique participants that are introducing cutting-edge therapies in this segment?
  • What are the strategic imperatives to be adopted by these participants to bring about this market transformation?
  • What is the growth potential of this rapidly expanding cell therapy market?
  • What are some key factors for success in the global cell therapy market?
More Information
No Index No
Podcast No
Author Aarti Chitale
Industries Healthcare
WIP Number PA16-01-00-00-00
Is Prebook No
GPS Codes 9600-B1,9571-B1,99C1-B1,9568-B1,9611-B1